CAJ | 학술논문

目的：观察布拉氏酵母菌散联合美沙拉嗪治疗溃疡性结肠炎( UC)患者的疗效及对血清白细胞介素因子水平的影响。方法将242例活动期UC患者随机分为观察组124例和对照组118例，对照组给予美沙拉嗪治疗，观察组在此基础上给予布拉氏酵母菌散治疗，对比两组疗效及血清白细胞介素-1(IL-1)、 IL-2、IL-8因子水平的变化。结果观察组总有效率显著高于对照组，差异有统计学意义(P<0．05)。治疗前观察组IL-1、IL-2、IL-8含量与对照组比较差异未见统计学意义( P>0．05)，治疗后IL-1和IL-8与对照组比较均降低，差异有统计学意义(P<0．05)，而血清中IL-2的含量在治疗后则有明显升高，且治疗组升高较对照组明显(P<0．05)。两组不良反应比较差异未见统计学意义(P>0．05)。结论布拉氏酵母菌散联合美沙拉嗪治疗UC 可明显提高治疗有效率，两者具有药物协同作用，能更好地控制病情，有较大的临床应用价值。
목적：관찰포랍씨효모균산연합미사랍진치료궤양성결장염( UC)환자적료효급대혈청백세포개소인자수평적영향。방법장242례활동기UC환자수궤분위관찰조124례화대조조118례，대조조급여미사랍진치료，관찰조재차기출상급여포랍씨효모균산치료，대비량조료효급혈청백세포개소-1(IL-1)、 IL-2、IL-8인자수평적변화。결과관찰조총유효솔현저고우대조조，차이유통계학의의(P<0．05)。치료전관찰조IL-1、IL-2、IL-8함량여대조조비교차이미견통계학의의( P>0．05)，치료후IL-1화IL-8여대조조비교균강저，차이유통계학의의(P<0．05)，이혈청중IL-2적함량재치료후칙유명현승고，차치료조승고교대조조명현(P<0．05)。량조불량반응비교차이미견통계학의의(P>0．05)。결론포랍씨효모균산연합미사랍진치료UC 가명현제고치료유효솔，량자구유약물협동작용，능경호지공제병정，유교대적림상응용개치。
Objective To evaluate the curative effect of Saccharomyces boulardii sachets com-bined with mesalazine and the influence on inflammatory factors in patients with ulcerative colitis. Methods Two hundred and forty-two patients with active ulcerative colitis were ran-domly divided into the observation group ( n=124 ) and the control group ( n=118 ) . The observation group were treated with Saccharomyces boulardii sachets combined with mesalazine while the control group were only treated with mesalazine. The curative effects of the two groups were compared. And the changes of IL-1, IL-2, IL-8 in serum of patients with ulcerative colitis in the two groups were also compared. Results The total efficiency in the observation group was higher than that in the control group and the difference was significant ( P<0. 05 ) . The con-centrations of IL-1 , IL-8 in the two groups were not significantly different from before treatment ( P >0. 05 ) . The concentrations of IL-1 and IL-8 were all lower in the observation group than those in the control group (P<0. 05),while IL-2 was reverse after treatment (P<0. 05) . The adverse reactions in the two groups were similar ( P>0. 05 ) . Conclusions Saccharomyces boulardii sachets combined with mesalazine can improve the effective rate of patients with active ulcerative colitis. The two drugs have synergistic effect and can control pathogenetic condition of patients with active ulcerative colitis. The two drugs can have better clinical application values and good application prospect.